TNF and inflammatory bowel disease: Infliximab (Remicade®) was the first anti-TNF-α, chimeric IgG1 monoclonal antibody (mAb), approved for IBD in 1998. Following that, other anti-TNF-α were approved such as adalimumab (Humira®) and golimumab (Simponi®), a fully human anti-TNF-α mAb.